Form 4: Kymera Therapeutics Director Elena Ridloff Granted 16,000 Stock Options

Kymera Therapeutics, Inc. director Elena Ridloff was granted 16,000 stock options with an exercise price of $46.47, vesting by June 25, 2026, or the next annual meeting.

Summary

• Elena Ridloff, a Director of Kymera Therapeutics, Inc. (KYMR), was granted 16,000 stock options.
• The options have an exercise price of $46.47 per share.
• The transaction date for this grant was June 25, 2025.
• These options are for 16,000 shares of Kymera Therapeutics Common Stock.
• The options will vest in full upon the earlier of June 25, 2026, or the date of the Issuer's next annual meeting of stockholders.
• The expiration date for these stock options is June 24, 2035.

Sentiment

Score: 6

Explanation: Slightly positive. A routine compensation grant to a director, which aligns interests, is generally viewed as a neutral to slightly positive event, indicating stability in governance and incentivization.

Positives

• The grant of stock options to Director Elena Ridloff aligns her interests with those of shareholders, incentivizing long-term performance.
• The vesting schedule provides a clear timeline for the options to become exercisable, promoting retention of key board members.

Future Outlook

The document indicates a future vesting event for the granted stock options, occurring by June 25, 2026, or the date of the next annual meeting, aligning the director's incentives with future company performance.

Industry Context

This stock option grant is a standard form of executive and director compensation within the biotechnology and pharmaceutical industries, aiming to align leadership interests with long-term shareholder value creation. It does not provide broader industry trends or competitive insights.

Comparison to Industry Standards

• The grant of stock options to a director is a common practice in the biotechnology sector, comparable to compensation structures seen at other publicly traded biopharmaceutical companies.
• The specific value and vesting terms would typically be benchmarked against peer group compensation data, though such comparative data is not provided in this filing.

Related Party Transactions

• The grant of 16,000 stock options to Elena Ridloff, a Director of Kymera Therapeutics, Inc., constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially leading to better long-term performance. However, it also represents potential future dilution if the options are exercised.

Next Steps

• The granted stock options will vest in full upon the earlier of June 25, 2026, or the date of the Issuer's next annual meeting of stockholders.

Key Dates

Keywords

Kymera Therapeutics, KYMR, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Elena Ridloff